WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Tuesday reported a loss of $4.6 million in its third quarter.
On a per-share basis, the Washington-based company said it had a loss of 10 cents.
The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was also for a loss of 10 cents per share.
The biopharmaceutical company posted revenue of $41.3 million in the period.
For the current quarter ending in December, Vanda said it expects revenue in the range of $42 million to $48 million.
The company expects full-year revenue in the range of $163 million to $169 million.
Vanda shares have fallen slightly more than 6 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $14.95, a climb of almost 3 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VNDA at https://www.zacks.com/ap/VNDA